Jim Simons
AMLX icon

Jim Simons’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jim Simons’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-192,500
Closed -$2.33M – 3226
2025
Q4 		$2.33M Buy
192,500
+172,600
+867% +$2.34M ﹤0.01% 1769
2025
Q3 		$270K Sell
19,900
-376,300
-95% -$3.54M ﹤0.01% 3043
2025
Q2 		$2.54M Sell
396,200
-118,900
-23% -$578K ﹤0.01% 1966
2025
Q1 		$1.82M Buy
515,100
+50,700
+11% +$180K ﹤0.01% 2065
2024
Q4 		$1.76M Buy
464,400
+192,600
+71% +$906K ﹤0.01% 2140
2024
Q3 		$881K Sell
271,800
-539,688
-67% -$1.21M ﹤0.01% 2525
2024
Q2 		$1.54M Buy
811,488
+106,888
+15% +$207K ﹤0.01% 2044
2024
Q1 		$2M Buy
704,600
+633,312
+888% +$8.28M ﹤0.01% 2031
2023
Q4 		$1.05M Sell
71,288
-78,812
-53% -$1.21M ﹤0.01% 2371
2023
Q3 		$2.75M Buy
+150,100
New +$3.17M ﹤0.01% 1676
2023
Q1 		– Sell
-178,300
Closed -$6.59M – 3945
2022
Q4 		$6.59M Buy
+178,300
New +$6.33M 0.01% 1336
2022
Q2 		– Sell
-146,400
Closed -$1.88M – 4191
2022
Q1 		$1.88M Buy
+146,400
New +$3.31M ﹤0.01% 2275

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Jim Simons's AMLX Position: Q1 2026 in Review

Jim Simons sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 192,500 shares — an estimated $2.33M sold.

Jim Simons first reported a position in AMLX in Q1 2022 and held it in 12 quarters. The position peaked at $6.59M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Jim Simons reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jim Simons sold 192,500 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $2.33M.
  • Jim Simons first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 12 quarters.
  • Jim Simons's Amylyx Pharmaceuticals position peaked at $6.59M in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.